On Dec. 7, 2020, Matinas BioPharma announced that they planned to collaborate with the National Institute of Allergy and Infectious Diseases (NIAID) to test oral formulations of remdesivir in preclinical models. Remdesivir is owned by Gilead Sciences and the lipid nanocrystal platform is owned by Matinas.